{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-082999","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.190744+00:00","generated_at":"2026-06-24T08:10:16.280987+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"medium","headline":"VYNE CSO presents InhiBET platform at B&T Cell-Mediated Autoimmune Conference","bullets":["CSO Iain Stuart, Ph.D., presented at B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.","Presentation covered the InhiBET platform for bromodomain & end terminal (BET) inhibitors in autoimmune disease.","No new clinical data, financial results, or guidance changes disclosed in the filing or presentation exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-082999","json":"https://secwatch.observer/filing/0001104659-22-082999.json","markdown":"https://secwatch.observer/filing/0001104659-22-082999.md","text":"https://secwatch.observer/filing/0001104659-22-082999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/0001104659-22-082999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/tm2221840d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:10:16.280987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}